215 related articles for article (PubMed ID: 34280258)
1. BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway.
Butler M; van Ingen Schenau DS; Yu J; Jenni S; Dobay MP; Hagelaar R; Vervoort BMT; Tee TM; Hoff FW; Meijerink JP; Kornblau SM; Bornhauser B; Bourquin JP; Kuiper RP; van der Meer LT; van Leeuwen FN
Blood; 2021 Dec; 138(23):2383-2395. PubMed ID: 34280258
[TBL] [Abstract][Full Text] [Related]
2. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
3. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
4. Bruton's tyrosine kinase drives neuroinflammation and anxiogenic behavior in mouse models of stress.
Ghosh S; Mohammed Z; Singh I
J Neuroinflammation; 2021 Dec; 18(1):289. PubMed ID: 34895246
[TBL] [Abstract][Full Text] [Related]
5. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia.
Bushman JE; Palmieri D; Whinna HC; Church FC
Leuk Res; 2000 Jul; 24(7):559-65. PubMed ID: 10867129
[TBL] [Abstract][Full Text] [Related]
6. Cathepsin B Is Not an Intrinsic Factor Related to Asparaginase Resistance of the Acute Lymphoblastic Leukemia REH Cell Line.
Costa IM; Effer B; Costa-Silva TA; Chen C; Ciccone MF; Pessoa A; Dos Santos CO; Monteiro G
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446393
[TBL] [Abstract][Full Text] [Related]
7. BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia.
Fiorcari S; Maffei R; Vallerini D; Scarfò L; Barozzi P; Maccaferri M; Potenza L; Ghia P; Luppi M; Marasca R
Front Immunol; 2020; 11():2158. PubMed ID: 32983178
[TBL] [Abstract][Full Text] [Related]
8. Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy.
Li YT; Kwon YM; Spangrude GJ; Liang JF; Chung HS; Park YJ; Yang VC
J Biomed Mater Res A; 2009 Oct; 91(1):209-20. PubMed ID: 18814276
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
Wang X; Fei Y; Liu X; Zhang T; Li W; Jia X; Liu X; Qiu L; Qian Z; Zhou S; Ren X; Zhai Q; Meng B; Li L; Zhang H
Aging (Albany NY); 2021 Sep; 13(17):21102-21121. PubMed ID: 34508613
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib in Gynecological Malignancies and Breast Cancer: A Systematic Review.
Metzler JM; Burla L; Fink D; Imesch P
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32532074
[TBL] [Abstract][Full Text] [Related]
11. Targeting Bruton's Tyrosine Kinase in CLL.
Ahn IE; Brown JR
Front Immunol; 2021; 12():687458. PubMed ID: 34248972
[TBL] [Abstract][Full Text] [Related]
12. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
13. Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
Chan WK; Horvath TD; Tan L; Link T; Harutyunyan KG; Pontikos MA; Anishkin A; Du D; Martin LA; Yin E; Rempe SB; Sukharev S; Konopleva M; Weinstein JN; Lorenzi PL
Mol Cancer Ther; 2019 Sep; 18(9):1587-1592. PubMed ID: 31209181
[TBL] [Abstract][Full Text] [Related]
14. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
Ran F; Liu Y; Wang C; Xu Z; Zhang Y; Liu Y; Zhao G; Ling Y
Eur J Med Chem; 2022 Feb; 229():114009. PubMed ID: 34839996
[TBL] [Abstract][Full Text] [Related]
15. Bruton's agammaglobulinemia tyrosine kinase (Btk) regulates TPA‑induced breast cancer cell invasion via PLCγ2/PKCβ/NF‑κB/AP‑1‑dependent matrix metalloproteinase‑9 activation.
Kim JM; Park J; Noh EM; Song HK; Kang SY; Jung SH; Kim JS; Park BH; Lee YR; Youn HJ
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760219
[TBL] [Abstract][Full Text] [Related]
16. Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines.
Su N; Pan YX; Zhou M; Harvey RC; Hunger SP; Kilberg MS
Pediatr Blood Cancer; 2008 Feb; 50(2):274-9. PubMed ID: 17514734
[TBL] [Abstract][Full Text] [Related]
17. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
[TBL] [Abstract][Full Text] [Related]
18. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
Tsurusawa M; Chin M; Iwai A; Nomura K; Maeba H; Taga T; Higa T; Kuno T; Hori T; Muto A; Yamagata M;
Cancer Chemother Pharmacol; 2004 Mar; 53(3):204-8. PubMed ID: 14634792
[TBL] [Abstract][Full Text] [Related]
19. Asparaginase pharmacology: challenges still to be faced.
Lanvers-Kaminsky C
Cancer Chemother Pharmacol; 2017 Mar; 79(3):439-450. PubMed ID: 28197753
[TBL] [Abstract][Full Text] [Related]
20. BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells.
Kong W; Sender S; Taher L; Villa-Perez S; Ma Y; Sekora A; Ruetgen BC; Brenig B; Beck J; Schuetz E; Junghanss C; Nolte I; Murua Escobar H
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
